Neoadjuvant Durvalumab Plus Weekly Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Triple-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
NPJ breast cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Durvalumab Plus Weekly Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Triple-Negative Breast Cancer
NPJ Breast Cancer 2021 Feb 08;[EPub Ahead of Print], J Foldi, A Silber, E Reisenbichler, K Singh, N Fischbach, J Persico, K Adelson, A Katoch, N Horowitz, D Lannin, A Chagpar, T Park, M Marczyk, C Frederick, T Burrello, E Ibrahim, T Qing, Y Bai, K Blenman, DL Rimm, L PusztaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.